01.12.2015 | Research article | Ausgabe 1/2015 Open Access

Anterior cruciate ligament remnant tissue harvested within 3-months after injury predicts higher healing potential
- Zeitschrift:
- BMC Musculoskeletal Disorders > Ausgabe 1/2015
Competing interests
Authors’ contributions
Background
Methods
Subjects
Cell isolation
ACL remnant tissue-derived cell characterization
Expansion potential assay
Multi-lineage differentiation assessment
Osteogenic differentiation
Endothelial differentiation
RNA extraction and quantitative reverse transcription-real-time polymerase chain reaction
Statistical analysis
Results
Demographic characteristics
Sex (male:female)
|
17:19
|
---|---|
Age, mean ± SD, year
|
|
10 ≤ age < 20,
n = 12
|
16.58 ± 1.68
|
20 ≤ age < 30,
n = 13
|
23.71 ± 2.78
|
≥ 30,
n = 11
|
35.10 ± 4.79
|
Interval from injury to surgery, day
|
|
< 90 days,
n = 18
|
48.9 ± 21.1
|
≥ 90 days,
n = 18
|
182.4 ± 91.0
|
Meniscal injury, case
|
18
|
Chondrl injury, case
|
3
|
Meniscus injury or cartilage degeneration, case
|
20
|
Predictors of risk factor
CD34+
|
CD44+
|
CD45+
|
CD146+
|
CD29+
|
Stro-1+
|
|||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
p
|
OR
|
95 % CI
|
p
|
OR
|
95 % CI
|
p
|
OR
|
95 % CI
|
p
|
OR
|
95 % CI
|
p
|
OR
|
95 % CI
|
p
|
OR
|
95 % CI
|
|
Interval from injury to surgery
b, < 90 days
|
0.025*
|
6.043
|
1.259–28.995
|
0.011*
|
8.440
|
1.615–44.111
|
0.015*
|
16.144
|
1.701–153.212
|
0.015*
|
9.246
|
1.541–55.461
|
0.369
|
1.982
|
0.446–8.819
|
0.059
|
4.559
|
0.944–22.020
|
10 ≤ age <20 year-old
c
|
0.957
|
1.056
|
0.144–7.755
|
0.996
|
0.994
|
0.124–7.985
|
0.773
|
1.370
|
0.161–11.643
|
0.416
|
0.438
|
0.060–3.198
|
0.960
|
1.048
|
0.167–6.572
|
0.112
|
6.244
|
0.679–40.503
|
20 ≤ age <30 year-old
c
|
0.027*
|
2.020
|
1.413–26.512
|
0.795
|
1.370
|
0.127–14.775
|
0.593
|
1.954
|
0.189–20.215
|
0.178
|
0.176
|
0.016–1.888
|
0.593
|
0.569
|
0.071–4.575
|
0.577
|
1.919
|
0.194–18.972
|
Sex
a Female
|
0.683
|
0.692
|
0.118–4.057
|
0.593
|
0.604
|
0.097–3.780
|
0.092
|
7.535
|
0.717–79.179
|
0.139
|
4.148
|
0.629–27.374
|
0.218
|
0.368
|
0.075–1.809
|
0.843
|
1.194
|
0.207–6.897
|
Meniscal injury
d
|
0.626
|
0.716
|
0.187–2.744
|
0.409
|
0.563
|
0.143–2.206
|
0.069
|
0.269
|
0.066–1.106
|
0.409
|
0.563
|
0.143–2.206
|
0.616
|
0.711
|
0.188–2.691
|
0.406
|
0.566
|
0.148–2.168
|
Chondral injury
d
|
0.433
|
2.714
|
0.223–32.992
|
0.327
|
3.500
|
0.286–42.769
|
0.761
|
0.679
|
0.056–8.248
|
0.327
|
3.500
|
0.286–42.769
|
0.554
|
2.125
|
0.175–25.775
|
0.688
|
0.600
|
0.049–7.283
|
Combined meniscal or chondral injuries
d
|
0.549
|
0.667
|
0.177–2.513
|
0.593
|
0.692
|
0.180–2.668
|
0.117
|
0.333
|
0.084–1.318
|
0.593
|
0.692
|
0.180–2.668
|
0.503
|
0.636
|
0.169–2.391
|
0.549
|
0.667
|
0.177–2.513
|
Passage 3
|
Passage 10
|
|||||
---|---|---|---|---|---|---|
p
|
OR
|
95 % CI
|
p
|
OR
|
95 % CI
|
|
Interval from injury to surgery
b, < 90 days
|
0.034*
|
9.755
|
1.187–80.186
|
0.003*
|
33.245
|
3.245–342.631
|
10 ≤ age <20 year-old
c
|
0.210
|
4.939
|
0.407–59.879
|
0.026*
|
25.141
|
1.484–426.057
|
20 ≤ age <30 year-old
c
|
0.521
|
2.250
|
0.189–26.831
|
0.339
|
3.528
|
0.267–46.676
|
Sex
a Female
|
0.576
|
1.794
|
0.232–13.909
|
0.230
|
3.156
|
0.483–20.619
|
Menical injury
d
|
0.632
|
1.400
|
0.354–5.542
|
0.406
|
1.768
|
0.461–6.775
|
Chondral injury
d
|
0.837
|
1.300
|
0.107–15.836
|
0.492
|
0.417
|
0.034–5.057
|
Combined meniscal or chondral injuries
d
|
0.593
|
1.444
|
0.375–5.566
|
0.334
|
1.929
|
0.509–7.311
|
ALP activity
|
Osteocalcin mRNA
|
ALP mRNA
|
Runx2 mRNA
|
|||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
p
|
OR
|
95 % CI
|
p
|
OR
|
95 % CI
|
p
|
OR
|
95 % CI
|
p
|
OR
|
95 % CI
|
|
Interval from injury to surgery
b, < 90 days
|
0.263
|
2.416
|
0.515–11.337
|
0.009*
|
20.579
|
2.119–199.882
|
0.022*
|
6.527
|
1.308–32.557
|
0.047*
|
5.247
|
1.023–26.922
|
10 ≤ age <20 year-old
c
|
0.895
|
0.884
|
0.142–5.491
|
0.384
|
2.683
|
0.290–24.782
|
0.962
|
0.954
|
0.141–6.481
|
0.592
|
0.600
|
0.092–3.895
|
20 ≤ age <30 year-old
c
|
0.240
|
0.277
|
0.033–2.356
|
0.909
|
1.155
|
0.097–13.787
|
0.742
|
1.420
|
0.176–11.451
|
0.480
|
0.463
|
0.055–3.924
|
Sex
a Female
|
0.030*
|
12.831
|
1.279–128.746
|
0.850
|
0.831
|
0.123–5.606
|
0.885
|
1.131
|
0.212–6.041
|
0.550
|
0.601
|
0.113–3.191
|
Meniscal injury
d
|
0.218
|
2.400
|
0.596–9.670
|
0.198
|
2.600
|
0.606–11.152
|
0.360
|
1.920
|
0.475–7.766
|
0.803
|
1.200
|
0.287–5.021
|
Chondral injury
d
|
0.000
|
0.000
|
0.000–0.000
|
1.000
|
1.000
|
0.081–12.270
|
0.000
|
0.000
|
0.000–0.000
|
0.913
|
1.150
|
0.093–14.188
|
Combined meniscal or chondral injuries
d
|
0.402
|
1.800
|
0.455–7.127
|
0.346
|
2.000
|
0.473–8.462
|
0.588
|
1.467
|
0.367–5.858
|
0.519
|
1.615
|
0.376–6.940
|
Tube length
|
VE-cadherin mRNA
|
CD31 mRNA
|
|||||||
---|---|---|---|---|---|---|---|---|---|
p
|
OR
|
95 % CI
|
p
|
OR
|
95 % CI
|
p
|
OR
|
95 % CI
|
|
Interval from injury to surgery
b, < 90 days
|
0.495
|
2.409
|
0.193–30.046
|
0.836
|
0.824
|
0.132–5.156
|
0.073
|
7.337
|
0.832–64.742
|
10 ≤ age <20 year-old
c
|
0.430
|
2.659
|
0.234–30.160
|
0.317
|
3.118
|
0.337–28.884
|
0.504
|
0.438
|
0.039–4.924
|
20 ≤ age <30 year-old
c
|
0.966
|
0.690
|
0.064–7.429
|
0.781
|
1.421
|
0.120–16.863
|
0.620
|
0.494
|
0.031–8.001
|
Sex
a Female
|
0.190
|
4.987
|
0.452–55.045
|
0.265
|
0.335
|
0.049–2.293
|
0.458
|
2.245
|
0.265–19.001
|
Meniscal injury
d
|
0.848
|
0.857
|
0.178–4.126
|
0.198
|
2.600
|
0.606–11.152
|
0.862
|
1.125
|
0.298–4.241
|
Chondral injury
d
|
0.547
|
0.458
|
0.036–6.789
|
0.000
|
0.000
|
0.000–0.000
|
0.619
|
0.531
|
0.044–6.444
|
Combined meniscal or condral injuries
d
|
0.966
|
1.010
|
0.214–4.674
|
0.346
|
2.000
|
0.473–8.462
|
0.765
|
0.818
|
0.219–3.056
|